Table 1

HLA-DR3-restricted T cell responses and HLA-DR3 binding of hsp65-derived peptides in humans or HLA-DR3.Ab0 mice

hsp65 amino acid sequenceRecognition by HLA-DR3-restricted T cells*HLA-DR3 binding affinity, IC50, μM
In humansIn tg mice
  1-20  MAKTIAYDEEARRGLERGLN++++++0.06
 41-60  KKWGAPTITNDGVSIAKEIE0.3
511-530 FLTTEAVVADKPEKEKASVP0.7
201-220 YFVTDPERQEAVLEDPYILL1.3
281-300 DRRKAMLQDMAILTGGQVIS1.7
211-230 AVLEDPYILLVSSKVSTVKD2
241-260 AGKPLLIIAEDVEGEALSTL2
481-500 VYEDLLAAGVADPVKVTRSA2.6
261-280 VVNKIRGTFKSVAVKAPGFG5
 81-100 DDVAGDGTTTATVLAQALVR6.5
181-200 FGLQLELTEGMRFDKGYISG9
321-340 VVVTKDETTIVEGAGDTDAI14
191-210 MRFDKGYISGYFVTDPERQE19
341-360 AGRVAQIRQEIENSDSDYDR20
401-420 AKAAVEEGIVAGGGVTLLQA20
441-460 KVALEAPLKQIAFNSGLEPG22
491-510 ADPVKVTRSALQNAASIAGL22
301-320 EEVGLTLENADLSLLGKARK25
171-190 GVITVEESNTFGLQLELTEG+26
331-350 VEGAGDTDAIAGRVAQIRQE28
 31-50  GPKGRNVVLEKKWGAPTITN30
All other peptides>100
  • DR3.Ab0 mice were immunized with BCG and hsp65 (10 μg per mouse). After 7 days, LNCs were challenged in vitro with hsp65− peptide (50 μg/ml). 

  • * Results for hsp65-reactive human T cells are shown for reference purposes only (see ref. 19). +++ indicates SI (stimulation index) ≥ 4; + indicates 2 ≤ SI ≤ 3; − indicates SI < 2. 

  • Peptide binding affinity (IC50) was defined as high-affinity (<1 μM), intermediate-affinity (1 μM to 10 μM), weak-affinity (10 μM to 100 μM), or nonbinding (>100 μM), according to ref. 27